瑞康医药：12月23日召开董事会会议

Group 1 - The core point of the article is that Ruikang Pharmaceutical announced a board meeting to discuss the proposal to change the accounting firm and provided details on its revenue composition for the first half of 2025 [1] - Ruikang Pharmaceutical's revenue for the first half of 2025 is primarily derived from drug and medical device sales, which account for 98.42% of total revenue, while mobile healthcare contributes 0.67%, other sources 0.6%, and leasing 0.31% [1] - As of the report, Ruikang Pharmaceutical has a market capitalization of 5.3 billion yuan [2]